Gregory Julien
Director, Financial Planning & Analysis and Corporate Development at Kronos Bio | Sunnyvale, California, United States
Gregory Julien’s Email & Phone Number
VerifiedFree account · No credit card · 5 profiles/month
Director, Financial Planning & Analysis and Corporate Development at Kronos Bio in June 2023 - November 2023
Associate Director, Financial Planning & Analysis at Revance in August 2018 - May 2023
Sr Manager, Clinical Finance at Myovant Sciences in March 2017 - August 2018
Sr Manager, Clinical Budgeting & Analysis at Medivation in January 2015 - March 2017
Senior Financial Analyst (Contract) at Actelion (now Janssen Pulmonary Hypertension) in January 2014 - January 2015
Finance Manager (Contract) at Sorbent Therapeutics, Inc. in January 2013 - January 2014
Manager, Contracts & Rebates at Gilead Sciences in January 2011 - January 2013
Sr Financial Analyst at Roche Molecular Systems in January 2009 - January 2011
Sr Financial Analyst, Financial Leadership Program at Agilent Technologies in January 2008 - January 2009
Manager, Financial Planning & Analysis at Nektar Therapeutics in January 2006 - January 2007
Senior Analyst, Finance & IM at Johnson & Johnson Innovative Medicine in January 1999 - January 2006
University of California, Berkeley - Walter A. Haas School of Business, January 2005 to January 2008
Kronos Bio is a clinical-stage biopharmaceutical company developing therapeutics that target the dysregulated transcription that causes cancer and other serious diseases. At Kronos Bio, we have two molecules that have emerged from our product engine. KB-0742, our CDK9 inhibitor, is being evaluated in a phase 1/2 clinical trial as a treatment for patients with MYC-dependent tumors such as triple negative breast cancer, non-small cell lung cancer and ovarian cancer, as well as patients with transcription factor fusion-driven cancers and other transcriptionally addicted cancers including chordomas, sarcomas and small cell lung cancer. Our new development candidate, KB-9558, targets the KAT domain of p300, a critical node of the IRF4 TRN, which is a core oncogenic transcription program that drives multiple myeloma. Additionally, Kronos Bio began a discovery collaboration with Genentech in January 2023. Our companies are working together to advance novel therapies against transcriptional targets in oncology. For additional information about our community guidelines, visit: https://bit.ly/3FfcDQW.
Discover more about Kronos Bio
Sr. Vice President, Biology at Kronos Bio, Inc.
Research Fellow at Dana Farber Cancer Institute
(August 2026 – August 2026)
Patient-centric drug discovery enthusiast
Senior Scientist, Translational Development at Kronos Bio
(March 2023 – November 2023)
Associate Director, Translation Operations at Kronos Bio, Inc.
Associate Director of Translation Operations at Kronos Bio, Inc.
(July 2021 – Present)
Senior Research Scientist at Kronos Bio, Inc.
Research Scientist II-Protein Characterizations at Charles River Laboratories
(August 2026 – August 2026)
In Vivo Pharmacology at Kronos Bio
Associate Scientist at Jounce Therapeutics, Inc.
(August 2026 – August 2026)
Senior Accountant at Kronos Bio, Inc.
Senior Accountant at Kronos Bio, Inc.
(January 2022 – Present)
What is Gregory Julien email address?
Email Gregory Julien at [email protected] and [email protected]. This email is the most updated Gregory Julien's email found in 2026.
How to contact Gregory Julien?
To contact Gregory Julien send an email to [email protected] or [email protected].
What company does Gregory Julien work for?
Gregory Julien works for Kronos Bio.
What is Gregory Julien's role at Kronos Bio?
Gregory Julien is Director, Financial Planning & Analysis and Corporate Development
